Evaluating the suitability of multitherapeutic contract research organizations (CROs) for clinical trials is crucial, as their broad capabilities may not always align with a sponsor’s specific needs. While such CROs can offer flexibility and extensive resources, partnering with them may sometimes lead to increased costs, extended timelines, and compromised data quality. This article delves into the scenarios where a multitherapeutic CRO is advantageous and highlights considerations to ensure optimal clinical trial outcomes.
